CAPR

About CAPR

Capricor Therapeutics, Inc. is a biotechnology company. The Company is focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). CAP-1002 is designed to slow disease progression in DMD through the immunomodulatory, anti-inflammatory, and anti-fibrotic actions of cardiosphere-derived cells (CDCs), which are mediated by secreted exosomes laden with bioactive cargo. CAP-2003 is the name of its exosomes product candidate, which is derived from its CDCs. It is also developing its exosome technology as a therapeutic platform. The Company’s focus is on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA), as well as proteins to treat or prevent a variety of diseases.